Lixte Biotechnology Holdings, a Phase 2 biotech using biomarker technology to develop protein inhibitors for cancer, filed on Thursday with the SEC to raise up to $11 million in an initial public offering. The company is currently listed on the OTC under the symbol "LIXT."
The company has developed two series of pharmacologically active drugs, the LB-100 series and the LB-200 series. The LB-100 series targets several types of cancer, with potential for vascular and metabolic diseases. The LB-200 series may be useful for the treatment of chronic hereditary diseases. The company completed a Phase 1 trial of LB-100 demonstrating antitumor activity in humans and is currently in a Phase 1b/2 trial, with results expected in 2023.
The East Setauket, NY-based company was founded in 2005 and plans to list on the Nasdaq under the symbol LIXT. WestPark Capital is the sole bookrunner on the deal.
